ArticlePloS one2024

A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients.

Li Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.